These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

399 related items for PubMed ID: 14981106

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations.
    Schrag D, Kuntz KM, Garber JE, Weeks JC.
    N Engl J Med; 1997 May 15; 336(20):1465-71. PubMed ID: 9148160
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis.
    Grann VR, Jacobson JS, Whang W, Hershman D, Heitjan DF, Antman KH, Neugut AI.
    Cancer J Sci Am; 2000 May 15; 6(1):13-20. PubMed ID: 10696733
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Quality of life and health status after prophylactic salpingo-oophorectomy in women who carry a BRCA mutation: A review.
    Finch A, Narod SA.
    Maturitas; 2011 Nov 15; 70(3):261-5. PubMed ID: 21893388
    [Abstract] [Full Text] [Related]

  • 10. Prophylactic oophorectomy and hormone replacement therapy: protection at what price?
    Garber JE, Hartman AR.
    J Clin Oncol; 2004 Mar 15; 22(6):978-80. PubMed ID: 14981100
    [No Abstract] [Full Text] [Related]

  • 11. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.
    Friebel TM, Domchek SM, Neuhausen SL, Wagner T, Evans DG, Isaacs C, Garber JE, Daly MB, Eeles R, Matloff E, Tomlinson G, Lynch HT, Tung N, Blum JL, Weitzel J, Rubinstein WS, Ganz PA, Couch F, Rebbeck TR.
    Clin Breast Cancer; 2007 Dec 15; 7(11):875-82. PubMed ID: 18269778
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.
    Kotsopoulos J, Lubinski J, Neuhausen SL, Lynch HT, Rosen B, Ainsworth P, Moller P, Ghadirian P, Isaacs C, Karlan B, Sun P, Narod SA.
    Gynecol Oncol; 2006 Jan 15; 100(1):83-8. PubMed ID: 16137751
    [Abstract] [Full Text] [Related]

  • 15. The quality of life associated with prophylactic treatments for women with BRCA1/2 mutations.
    Grann VR, Jacobson JS, Sundararajan V, Albert SM, Troxel AB, Neugut AI.
    Cancer J Sci Am; 1999 Jan 15; 5(5):283-92. PubMed ID: 10526669
    [Abstract] [Full Text] [Related]

  • 16. Predictors of prophylactic bilateral salpingo-oophorectomy compared with gynecologic screening use in BRCA1/2 mutation carriers.
    Madalinska JB, van Beurden M, Bleiker EM, Valdimarsdottir HB, Lubsen-Brandsma L, Massuger LF, Mourits MJ, Gaarenstroom KN, van Dorst EB, van der Putten H, Boonstra H, Aaronson NK.
    J Clin Oncol; 2007 Jan 20; 25(3):301-7. PubMed ID: 17235045
    [Abstract] [Full Text] [Related]

  • 17. Randomized trial of a shared decision-making intervention consisting of trade-offs and individualized treatment information for BRCA1/2 mutation carriers.
    van Roosmalen MS, Stalmeier PF, Verhoef LC, Hoekstra-Weebers JE, Oosterwijk JC, Hoogerbrugge N, Moog U, van Daal WA.
    J Clin Oncol; 2004 Aug 15; 22(16):3293-301. PubMed ID: 15310772
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.